[go: up one dir, main page]

IL144866A0 - N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance - Google Patents

N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Info

Publication number
IL144866A0
IL144866A0 IL14486600A IL14486600A IL144866A0 IL 144866 A0 IL144866 A0 IL 144866A0 IL 14486600 A IL14486600 A IL 14486600A IL 14486600 A IL14486600 A IL 14486600A IL 144866 A0 IL144866 A0 IL 144866A0
Authority
IL
Israel
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
IL14486600A
Other languages
English (en)
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of IL144866A0 publication Critical patent/IL144866A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14486600A 1999-02-26 2000-02-24 N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance IL144866A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (fr) 1999-02-26 2000-02-24 Chlorure de n-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxyde-3-carboximidoyl et ses utilisations dans le traitement de la resistance a l'insuline

Publications (1)

Publication Number Publication Date
IL144866A0 true IL144866A0 (en) 2002-06-30

Family

ID=90014224

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14486600A IL144866A0 (en) 1999-02-26 2000-02-24 N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
IL144866A IL144866A (en) 1999-02-26 2001-08-13 N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144866A IL144866A (en) 1999-02-26 2001-08-13 N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance

Country Status (27)

Country Link
US (1) US6649628B1 (fr)
EP (1) EP1163224B1 (fr)
JP (1) JP4689838B2 (fr)
KR (1) KR100676124B1 (fr)
AT (1) ATE237590T1 (fr)
AU (1) AU779096B2 (fr)
BG (1) BG65178B1 (fr)
BR (1) BR0008969A (fr)
CA (1) CA2360451C (fr)
CZ (1) CZ297386B6 (fr)
DE (1) DE60002187T2 (fr)
DK (1) DK1163224T3 (fr)
EE (1) EE04961B1 (fr)
ES (1) ES2193055T3 (fr)
HR (1) HRP20010584B1 (fr)
HU (1) HUP9900475D0 (fr)
IL (2) IL144866A0 (fr)
NO (1) NO319793B1 (fr)
PL (1) PL197692B1 (fr)
PT (1) PT1163224E (fr)
RS (1) RS50083B (fr)
RU (1) RU2250901C2 (fr)
SI (1) SI1163224T1 (fr)
SK (1) SK287063B6 (fr)
UA (1) UA72495C2 (fr)
WO (1) WO2000050403A1 (fr)
ZA (1) ZA200106488B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
MXPA04006716A (es) * 2002-01-11 2004-11-10 Biorex Kutato Es Rejleszt Rt Derivados de carboxamidina y su uso en el tratamiento de enfermedades vasculares.
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
DK2318032T3 (da) 2008-06-26 2012-06-11 Orphazyme Aps Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
WO2010058779A1 (fr) 2008-11-18 2010-05-27 参天製薬株式会社 Agent thérapeutique pour maladies dégénératives choriorétiniennes comprenant un dérivé de la pyridine-3-carbaldéhyde o-(pipéridine-1-yl-propyl)-oxime en tant qu'ingrédient actif
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
NZ706356A (en) * 2012-09-06 2018-02-23 Mcpharma Biotech Inc Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
CA2884777C (fr) 2012-09-14 2018-02-27 Saint-Gobain Glass France Vitre dotee d'un element de raccordement electrique
WO2015015248A1 (fr) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% Utilisation de composés présentant des propriétés co-induisant la protéine de choc thermique (hsp) pour améliorer l'effet de sensibilisation à l'insuline dans le traitement du diabète de type 2
CN107106494B (zh) * 2014-09-15 2021-12-21 奥菲泽米有限公司 阿瑞洛莫制剂
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
HRP20210047T1 (hr) 2016-04-29 2021-04-16 Orphazyme A/S, c/o COBIS A/S Arimoclomol za liječenje poremećaja povezanih s glukocerebrozidazom
BR112019024667A2 (pt) 2017-05-24 2020-06-16 Orphazyme A/S Uso de um agente bioativo, e, de uma composição
AU2019276048B2 (en) 2018-05-28 2025-09-04 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (fr) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'une maladie de niemann-pick de type c
IL299250A (en) 2020-06-24 2023-02-01 Kempharm Denmark As Arimoclomol for the treatment of Gaucher disease
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
MX2023007551A (es) 2020-12-24 2023-09-04 Zevra Denmark As Arimoclomol para el tratamiento de la enfermedad de niemann pick, tipo c, en pacientes con mutaciones de sentido erroneo de tipo reticulo endoplasmatico (er).

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
ZA200106488B (en) 2002-08-07
HUP9900475D0 (en) 1999-04-28
CZ20013053A3 (cs) 2002-01-16
EE04961B1 (et) 2008-02-15
SI1163224T1 (en) 2003-08-31
KR20010102410A (ko) 2001-11-15
CA2360451A1 (fr) 2000-08-31
DK1163224T3 (da) 2003-08-04
PT1163224E (pt) 2003-07-31
ATE237590T1 (de) 2003-05-15
UA72495C2 (uk) 2005-03-15
YU60301A (sh) 2004-05-12
NO319793B1 (no) 2005-09-12
ES2193055T3 (es) 2003-11-01
SK287063B6 (sk) 2009-10-07
RS50083B (sr) 2009-01-22
PL350915A1 (en) 2003-02-10
DE60002187D1 (de) 2003-05-22
HRP20010584B1 (en) 2010-08-31
IL144866A (en) 2007-07-04
NO20014103D0 (no) 2001-08-23
HRP20010584A2 (en) 2002-08-31
SK11582001A3 (sk) 2001-12-03
EP1163224B1 (fr) 2003-04-16
EP1163224A1 (fr) 2001-12-19
CA2360451C (fr) 2011-01-04
WO2000050403A1 (fr) 2000-08-31
PL197692B1 (pl) 2008-04-30
BG65178B1 (bg) 2007-05-31
EE200100447A (et) 2002-12-16
RU2250901C2 (ru) 2005-04-27
BR0008969A (pt) 2001-11-27
JP2002537384A (ja) 2002-11-05
JP4689838B2 (ja) 2011-05-25
DE60002187T2 (de) 2003-12-11
BG105837A (en) 2002-03-29
US6649628B1 (en) 2003-11-18
AU779096B2 (en) 2005-01-06
AU3182400A (en) 2000-09-14
NO20014103L (no) 2001-10-22
KR100676124B1 (ko) 2007-01-31
CZ297386B6 (cs) 2006-11-15

Similar Documents

Publication Publication Date Title
PL350915A1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
GB0223038D0 (en) Therapeutic compounds
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
CA2361834A1 (fr) Profils d'ablation decales pour le traitement de l'astigmatisme irregulier
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
WO1999063977A3 (fr) Composition pharmaceutique destinee a traiter ou prevenir les troubles du sommeil
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
EE200400032A (et) Polüfenooliühendit sisaldav farmatseutiline toitekompositsioon ning selle kasutamine vähktõve ravimiseks
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
CA2412789A1 (fr) Compositions destinees a ameliorer la concentration mentale
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
IL153733A0 (en) A new use for deferiprone
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
BG105204A (en) Salts of paroxetine
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
WO1999051216A3 (fr) Preparations pharmaceutiques et leur modes d'utilisation
TW200503999A (en) Therapeutic agents
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed